NCT06287099View on ClinicalTrials.gov

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

NANot yet recruitingINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

October 20, 2025

Study Completion Date

May 10, 2026

Conditions

Sickle Cell Disease

Interventions

DRUG

BRL-101

Subjects will receive a single infusion of BRL-101.

Sponsors

Lead Sponsor

Bioray Laboratories

All Listed Sponsors

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT06287099 - Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease | Biotech Hunter | Biotech Hunter